Clinical Trials
3 trialsNCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated